WO2002069888A3 - Serotonin reuptake inhibitor formulations - Google Patents

Serotonin reuptake inhibitor formulations Download PDF

Info

Publication number
WO2002069888A3
WO2002069888A3 PCT/US2002/004401 US0204401W WO02069888A3 WO 2002069888 A3 WO2002069888 A3 WO 2002069888A3 US 0204401 W US0204401 W US 0204401W WO 02069888 A3 WO02069888 A3 WO 02069888A3
Authority
WO
WIPO (PCT)
Prior art keywords
serotonin reuptake
reuptake inhibitor
hydrochloride
inhibitor formulations
water
Prior art date
Application number
PCT/US2002/004401
Other languages
French (fr)
Other versions
WO2002069888A2 (en
Inventor
Chih-Ming Chen
Boyong Li
Janice Cacace
Original Assignee
Andrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Corp filed Critical Andrx Corp
Priority to AU2002306491A priority Critical patent/AU2002306491A1/en
Publication of WO2002069888A2 publication Critical patent/WO2002069888A2/en
Publication of WO2002069888A3 publication Critical patent/WO2002069888A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

A process for preparing amorphous paroxetine hydrochloride or sertraline hydrochloride is provided, which comprises preparing a solution in which paroxetine hydrochloride or sertraline hydrochloride and a water-soluble polymer is dissolved in a co-solvent of a volatile organic solvent and water. Said solution is dried to obtain a composition comprising amorphous paroxetine hydrochloride or sertraline hydrochloride and the water-soluble matrix.
PCT/US2002/004401 2001-02-16 2002-02-14 Serotonin reuptake inhibitor formulations WO2002069888A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002306491A AU2002306491A1 (en) 2001-02-16 2002-02-14 Serotonin reuptake inhibitor formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/785,040 US6720003B2 (en) 2001-02-16 2001-02-16 Serotonin reuptake inhibitor formulations
US09/785,040 2001-02-16

Publications (2)

Publication Number Publication Date
WO2002069888A2 WO2002069888A2 (en) 2002-09-12
WO2002069888A3 true WO2002069888A3 (en) 2002-12-27

Family

ID=25134289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/004401 WO2002069888A2 (en) 2001-02-16 2002-02-14 Serotonin reuptake inhibitor formulations

Country Status (3)

Country Link
US (2) US6720003B2 (en)
AU (1) AU2002306491A1 (en)
WO (1) WO2002069888A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
WO2003020717A1 (en) * 2001-08-02 2003-03-13 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
WO2003057150A2 (en) * 2001-12-28 2003-07-17 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
GB2392385A (en) * 2002-09-02 2004-03-03 Cipla Ltd Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
US6939877B2 (en) * 2002-09-12 2005-09-06 Wyeth Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
US20050181049A1 (en) * 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
EP1691788A2 (en) * 2003-11-21 2006-08-23 Schering Corporation Phosphodiesterase v inhibitor formulations
US7994225B2 (en) 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
WO2005107716A1 (en) * 2004-03-25 2005-11-17 Cadila Healthcare Limited Controlled release paroxetine-containing tablets based on a core and a coating
US20050250738A1 (en) * 2004-05-06 2005-11-10 Mosher Gerold L Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
CA2615452C (en) 2005-07-15 2015-03-31 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US20090062909A1 (en) * 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
CA2616383C (en) * 2005-07-29 2015-06-09 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
KR100591142B1 (en) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 A enteric sustained-release tablet comprising paroxetine
EP1942872A2 (en) * 2005-11-04 2008-07-16 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
WO2007052152A2 (en) * 2005-11-07 2007-05-10 Aurobindo Pharma Limited Sertraline oral concentrate
EP1948646A2 (en) * 2005-11-14 2008-07-30 Auspex Pharmaceuticals Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
CA2996768C (en) 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
WO2008042909A2 (en) 2006-10-02 2008-04-10 Micell Technologies Inc. Surgical sutures having increased strength
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
CA2667228C (en) 2006-10-23 2015-07-14 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
AU2008256684B2 (en) * 2007-05-25 2012-06-14 Micell Technologies, Inc. Polymer films for medical device coating
EP2200997B9 (en) * 2007-09-13 2016-01-13 Concert Pharmaceuticals Inc. Synthesis of deuterated benzodioxoles
CA2700844A1 (en) * 2007-09-25 2009-04-02 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
EP2271294B1 (en) 2008-04-17 2018-03-28 Micell Technologies, Inc. Stents having bioabsorbable layers
JP2011528275A (en) 2008-07-17 2011-11-17 ミセル テクノロジーズ，インク． Drug delivery medical device
DE102008047910A1 (en) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose
US8834913B2 (en) * 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
CA2756307C (en) * 2009-03-23 2017-08-08 Micell Technologies, Inc. Peripheral stents having layers and reinforcement fibers
WO2010111238A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Improved biodegradable polymers
US20100239635A1 (en) * 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
CN102481195B (en) * 2009-04-01 2015-03-25 米歇尔技术公司 Drug delivery medical device
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc Drug delivery medical device
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10702485B2 (en) * 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
JP6285865B2 (en) 2011-11-14 2018-02-28 アルファシグマ ソシエタ ペル アチオニ Assays and methods for selecting treatment regimens for subjects with depression
BR102012009317B1 (en) * 2012-04-20 2022-05-31 Universidade Federal De Minas Gerais - Ufmg Process of preparation of inclusion compounds involving cyclodextrins and drugs, using a continuous flow system
KR20150143476A (en) 2013-03-12 2015-12-23 미셀 테크놀로지즈, 인코포레이티드 Bioabsorbable biomedical implants
KR102079613B1 (en) 2013-05-15 2020-02-20 미셀 테크놀로지즈, 인코포레이티드 Bioabsorbable biomedical implants
JP6455293B2 (en) * 2015-04-21 2019-01-23 ニプロ株式会社 Formulation containing sertraline and / or a pharmaceutically acceptable salt thereof
CN104997741A (en) * 2015-06-24 2015-10-28 万特制药(海南)有限公司 Orally disintegrating tablet containing sertraline and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4356518A (en) 1980-02-01 1982-10-26 Ampex Corporation High frequency digital PCM decoding apparatus
DE3688827T2 (en) 1985-10-25 1994-03-31 Beecham Group Plc Piperidine derivative, its manufacture and its use as a medicine.
IT1188212B (en) 1985-12-20 1988-01-07 Paolo Colombo SYSTEM FOR THE RELEASE SPEED OF ACTIVE SUBSTANCES
US4839104A (en) 1987-06-11 1989-06-13 Pfizer, Inc. Process for preparing sertraline intermediates
US4772288A (en) 1987-06-15 1988-09-20 Borner William H Method for producing implantable ligament and tendon prostheses and prostheses produced thereby
US4855500A (en) 1988-05-04 1989-08-08 Pfizer Inc. Process for preparing a ketimine
IT1237904B (en) 1989-12-14 1993-06-18 Ubaldo Conte CONTROLLED SPEED RELEASE TABS OF ACTIVE SUBSTANCES
US5082970A (en) 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5196607A (en) 1992-02-14 1993-03-23 Pfizer Inc. Process for preparing ketone enantiomer
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
GB9305175D0 (en) 1993-03-13 1993-04-28 Smithkline Beecham Plc Novel process
ATE159706T1 (en) 1993-11-30 1997-11-15 Pfizer METHOD FOR PRODUCING CHIRAL TETRALONS
GB9402029D0 (en) 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5856493A (en) 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
US5734083A (en) 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
US5672612A (en) 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
AU3108097A (en) 1997-06-10 1998-12-30 Synthon B.V. 4-phenylpiperidine compounds
US5955475A (en) 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
GB9724544D0 (en) 1997-11-21 1998-01-21 Smithkline Beecham Plc Novel Formulation
US6168805B1 (en) 1998-05-07 2001-01-02 Endo Pharmaceuticals, Inc. Aqueous process for manufacturing paroxetine solid dispersions
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof

Also Published As

Publication number Publication date
AU2002306491A1 (en) 2002-09-19
US20050027011A1 (en) 2005-02-03
US20020156066A1 (en) 2002-10-24
WO2002069888A2 (en) 2002-09-12
US6720003B2 (en) 2004-04-13

Similar Documents

Publication Publication Date Title
WO2002069888A3 (en) Serotonin reuptake inhibitor formulations
DE69906269T2 (en) AQUEOUS PROCESS FOR PRODUCING SOLID PAROXETINE DISPERSIONS
CA2387517A1 (en) Novel biaryl ether derivatives useful as monoamine reuptake inhibitors
ATE355829T1 (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING A LIPOPHILIC ACTIVE INGREDIENT AND THE PRODUCTION THEREOF
WO2004047830A3 (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
NL1015471A1 (en) Organic anti-reflective polymer and method for its preparation.
HRP20050263B1 (en) Pyrrolidone derivatives as maob inhibitors
ME01361B (en) Pharmaceutical composition containing fenofibrate and preparation method
CY1108551T1 (en) BETAUSTIN'S CONTROLLED LIBERTY COMPOSITIONS
WO2006026174A3 (en) Matrix composition for stable microemulsions
EP1661893A3 (en) Process for the preparation of threo-1,2-epoxy-3-amino-4-phenylbutane derivatives
ITMI20001093A0 (en) CONTROLLED RELEASE COMPOSITIONS CONTAINING AN ACTIVE INGREDIENT, PREFERABLY MELATONIN, AND THEREOF PREPARATION PROCESS.
GB2364317B (en) Organic anti-reflective coating polymer,anti-reflective coating composition comprising the same and method of preparation thereof
ITTO20001220A0 (en) ORGANIC POLYMER FOR ANTI-REFLECTIVE COATING AND ITS PREPARATION.
GB0115795D0 (en) Organic anti-reflective coating polymer,anti-reflective coating composition comprising the same and preparation methods thereof
EP1897867A4 (en) Compounds, preparation process, and uses thereof used for interrupting reuptake of 5-hydroxytryptamine and norepinephrine or treating diseases such as depression et al.
HRP20090190T1 (en) Pharmaceutical composition comprising a salt of mirtazapine
DE60107639D1 (en) Polymer, resist composition and pattern transfer process
IT1320211B1 (en) ANTI-REFLECTIVE ORGANIC POLYMERS FOR COATINGS AND THEIR PREPARATION PROCEDURES.
AR048756A1 (en) PROCEDURE TO FORM AMORFA ATORVASTATIN
DE60137280D1 (en) Polymer, resist composition and pattern transfer process
GB0115816D0 (en) Organic anti-reflective coating polymer,anti-reflective coating composition comprising the same and method of preparation thereof
NO20031108D0 (en) Pharmaceutical composition for the treatment of headache, and method for the preparation of the preparation
NO321301B1 (en) Formulation for treating wood, including a mixture of solutions containing styrene and furfuryl alcohol, and processes for the preparation and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP